All subsequent outpatients. The first three of them received five unilateral injections in the L2-L4 lumbar segments. The next two have received 10 unilateral injections in the same region. Future patients will all ambulatory with sequential levels of disability. If and and the study of the the safety monitoring board , is the study of cervical transplantation progress.. About the StudyThis phase I trial evaluating the safety of the cells and the surgery procedure, is designed to enroll up to 18 ALS patients in different stages of the disease process. 11 patients have been treated. The first six were non – ambulatory.

Feldman, director of the director first nine A. Alfred Taubman Medical Research Institute and Director of Research of the ALS Clinic at the University of Michigan Health System will present preliminary data on the safety of the first nine patients in the study. Feldman presentation was also elected Dr. Be highlighted in the Scientific Program Highlights Plenary Session by the chairman of the AAN Science Committee at 5:15 on the 15th April taught. Inclusion in this session is by invitation only; Dr. Feldman was as presentation by the Committee in the top 5 percent of submitted abstracts, which may be in the thousands..The device is intended for use in at any one plane or two contiguous levels in the treatment of degenerative disk disease with up to levels I spondylolisthesis. The system of Xiphos implants are also for use suggested a vertebra a vertebral body that has been resected or excised because tumor or trauma / fracture. The system for which thoracic and lumbar spinal intended and be designed for use with an additional internal fixation. By Dr. Milestone in the commercial way DIFUSION that non only that it us at an early stage revenue source, to Xiphos line is also a platform for us be CleanFUZE CleanFUZE line of the fusion device, said John calves, Chairman the DIFUSION Electronics.. DIFUSION Electronics Inc., a medical device company in developing and marketing of its proprietary CleanFUZE concentrated antimicrobial technology orthopedic implant, today announced to clearance for the the new Xiphos lines of the the rear interbody equipment specify of intervertebral body fusion of the lumbar spine, from L2 to SI, in the skeletally immature patients who who six months non-operative treatment.